2026-04-29T12:24:05Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/204662024-11-28T20:00:56Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967col_20.500.12105_16971col_20.500.12105_16983

00925njm 22002777a 4500 dc Keller, Benjamin author Mestre-Pinto, Joan-Ignasi author Alvaro-Bartolome, Maria author Martinez-Sanvisens, Diana author Farre, Magi author Julia Garcia-Fuster, M author Garcia-Sevilla, Jesus A author Torrens, Marta author NEURODEP Grp author 2017-12-01 The association of cocaine use disorder (CUD) and comorbid major depressive disorder (MDD; CUD/MDD) is characterized by high prevalence and poor treatment outcomes. CUD/MDD may be primary (primary MDD) or cocaine-induced (CUD-induced MDD). Specific biomarkers are needed to improve diagnoses and therapeutic approaches in this dual pathology. Platelet biomarkers [5-HT2A receptor and imidazoline receptor antisera selected (IRAS)/nischarin] were assessed by Western blot in subjects with CUD and primary MDD (n = 16) or CUD-induced MDD (n = 9; antidepressant free, AD-; antidepressant treated, AD+) and controls (n = 10) at basal level and/or after acute tryptophan depletion (ATD). Basal platelet 5-HT2A receptor (monomer) was reduced in comorbid CUD/MDD subjects (all patients: 43%) compared to healthy controls, and this down-regulation was independent of AD medication (decreases in AD-: 47%, and in AD+: 40%). No basal differences were found for IRAS/nischarin contents in AD+ and AD-comorbid CUD/MDD subjects. The comparison of IRAS/nischarin in the different subject groups during/after ATD showed opposite modulations (i.e., increases and decreases) in response to low plasma tryptophan levels with significant differences discriminating between the subgroups of CUD with primary MDD and CUD-induced MDD. These specific alterations suggested that platelet IRAS/nischarin might be useful as a biomarker to discriminate between primary and CUD-induced MDD in this dual pathology. Keller B, Mestre-Pinto JI, Alvaro-Bartolome M, Martinez-Sanvisens D, Farre M, García-Fuster MJ, et al. A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor). Front Psychiatry. 2017 Dec 01;8:258. 10.3389/fpsyt.2017.00258 1664-0640 Frontiers in Psychiatry http://hdl.handle.net/20.500.13003/9541 29326609 L619582782 2-s2.0-85037623572 http://hdl.handle.net/20.500.12105/20466 416792100001 Platelet biomarker IRAS/nischarin Cocaine use disorder Major depressive disorder Cocaine-induced depression Acute tryptophan depletion Antidepressant drugs A Biomarker to Differentiate between Primary and Cocaine-Induced Major Depression in Cocaine Use Disorder: The Role of Platelet IRAS/Nischarin (I-1-Imidazoline Receptor)